This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Warby Parker (WRBY) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Warby Parker (WRBY) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Warby Parker Inc. (WRBY) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Warby Parker (WRBY) delivered earnings and revenue surprises of 20% and 0.71%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Aurora Cannabis Inc. (ACB) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aurora Cannabis (ACB) delivered earnings and revenue surprises of 68.57% and 20.16%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Earnings Estimates Moving Higher for Warby Parker (WRBY): Time to Buy?
by Zacks Equity Research
Warby Parker (WRBY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Warby Parker Inc. (WRBY) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Warby Parker Inc. (WRBY) have what it takes to be a top stock pick for momentum investors? Let's find out.
Warby Parker (WRBY) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Warby Parker (WRBY) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zimmer Biomet (ZBH) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Zimmer (ZBH) delivered earnings and revenue surprises of 3.74% and 1.16%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Warby Parker Inc. (WRBY) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Warby Parker Inc. (WRBY) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Warby Parker Inc. (WRBY) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
Although the revenue and EPS for Warby Parker Inc. (WRBY) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Pre-Markets in the Green Ahead of CPI Data Release
by Zacks Equity Research
Pre-Markets in the Green Ahead of CPI Data Release
Markets Climbing Back; WEN, RBLX, WRBY Report, DIS After the Close
by Mark Vickery
While Wendy's and Roblox merely met EPS expectations, Warby Parker posted a strong quarter.
Compared to Estimates, Warby Parker Inc. (WRBY) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Warby Parker Inc. (WRBY) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Warby Parker Inc. (WRBY) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Warby Parker Inc. (WRBY) delivered earnings and revenue surprises of 100% and 2.76%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
ResMed (RMD) Misses Q4 Earnings Estimates
by Zacks Equity Research
ResMed (RMD) delivered earnings and revenue surprises of -4.19% and 0.36%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Zacks.com featured highlights include Catalyst Pharmaceuticals, Warby Parker, MakeMyTrip Ltd., Brookfield Renewable Partners & Century Aluminum
by Zacks Equity Research
Catalyst Pharmaceuticals, Warby Parker, MakeMyTrip Ltd., Brookfield Renewable Partners & Century Aluminum are part of the Zacks Screen of the Week article.
5 Stocks to Keep a Tab on for Solid Earnings Acceleration
by Tirthankar Chakraborty
Notable companies to have witnessed earnings acceleration as of now are Catalyst Pharmaceuticals (CPRX), Warby Parker (WRBY), MakeMyTrip (MMYT), Brookfield Renewable Partners (BEP) & Century Aluminum (CENX).
Warby Parker Inc. (WRBY) Q3 Earnings Match Estimates
by Zacks Equity Research
Warby Parker Inc. (WRBY) delivered earnings and revenue surprises of 0% and 2.61%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
RadNet (RDNT) Misses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
RadNet (RDNT) delivered earnings and revenue surprises of -43.75% and 0.04%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
AdaptHealth Corp. (AHCO) Misses Q3 Earnings Estimates
by Zacks Equity Research
AdaptHealth Corp. (AHCO) delivered earnings and revenue surprises of -64.52% and 2.43%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Do Options Traders Know Something About Warby Parker (WRBY) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Warby Parker (WRBY) stock based on the movements in the options market lately.
Implied Volatility Surging for Warby Parker (WRBY) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Warby Parker (WRBY) stock based on the movements in the options market lately.
Company News for May 17, 2022
by Zacks Equity Research
Companies in The News Are: WIX,YOU,WEBR,WRBY
US Stock Market Consolidates Ahead Of The Fed's Pivotal Liftoff Meeting
by Daniel Laboe
Get ready for what promises to be one of the most important weeks of market-moving action as investors' focus shifts towards the Federal Reserve
Market Bears Take The Bulls By The Horns As Q4 Kicks Off
by Daniel Laboe
We are not out of the correction woods yet as mega-cap tech breaks below Friday's lows